Literature DB >> 27263112

mTOR Signaling in Parkinson's Disease.

Ai-Ping Lan1, Jun Chen1, Yuliang Zhao1, Zhifang Chai1, Yi Hu2.   

Abstract

As a key regulator of cell metabolism and survival, mechanistic target of rapamycin (mTOR) emerges as a novel therapeutic target for Parkinson's disease (PD). A growing body of research indicates that restoring perturbed mTOR signaling in PD models can prevent neuronal cell death. Nevertheless, molecular mechanisms underlying mTOR-mediated effects in PD have not been fully understood yet. Here, we review recent progress in characterizing the association of mTOR signaling with PD risk factors and further discuss the potential roles of mTOR in PD.

Entities:  

Keywords:  Apoptosis; Oxidative stress; Parkinson’s disease; mTOR; α-Synuclein

Mesh:

Substances:

Year:  2016        PMID: 27263112     DOI: 10.1007/s12017-016-8417-7

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  24 in total

1.  Low-concentration DMSO accelerates skin wound healing by Akt/mTOR-mediated cell proliferation and migration in diabetic mice.

Authors:  Wei Guo; Wei Qiu; Xiang Ao; Weiqiang Li; Xiao He; Luoquan Ao; Xueting Hu; Zhan Li; Ming Zhu; Donglin Luo; Wei Xing; Xiang Xu
Journal:  Br J Pharmacol       Date:  2020-04-07       Impact factor: 8.739

Review 2.  Antiaging Therapies, Cognitive Impairment, and Dementia.

Authors:  Devin Wahl; Rozalyn M Anderson; David G Le Couteur
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-09-16       Impact factor: 6.053

Review 3.  Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life Expectancy.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2016       Impact factor: 1.990

4.  A metabolomic signature of treated and drug-naïve patients with Parkinson's disease: a pilot study.

Authors:  Jacopo Troisi; Annamaria Landolfi; Carmine Vitale; Katia Longo; Autilia Cozzolino; Massimo Squillante; Maria Cristina Savanelli; Paolo Barone; Marianna Amboni
Journal:  Metabolomics       Date:  2019-06-10       Impact factor: 4.290

Review 5.  Mechanistic target of rapamycin signaling in mouse models of accelerated aging.

Authors:  Jin Young Lee; Brian K Kennedy; Chen-Yu Liao
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-01-01       Impact factor: 6.053

6.  Dopamine neuron morphology and output are differentially controlled by mTORC1 and mTORC2.

Authors:  Polina Kosillo; Kamran M Ahmed; Erin E Aisenberg; Vasiliki Karalis; Bradley M Roberts; Stephanie J Cragg; Helen S Bateup
Journal:  Elife       Date:  2022-07-26       Impact factor: 8.713

7.  mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis.

Authors:  Jose-Alberto Palma; Jose Martinez; Patricio Millar Vernetti; Thong Ma; Miguel A Perez; Judy Zhong; Yingzhi Qian; Suman Dutta; Katherine N Maina; Ibrar Siddique; Gal Bitan; Benjamin Ades-Aron; Timothy M Shepherd; Un J Kang; Horacio Kaufmann
Journal:  Mov Disord       Date:  2022-01-18       Impact factor: 9.698

Review 8.  mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases.

Authors:  Hannah E Walters; Lynne S Cox
Journal:  Int J Mol Sci       Date:  2018-08-08       Impact factor: 5.923

Review 9.  Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration.

Authors:  Henry Querfurth; Han-Kyu Lee
Journal:  Mol Neurodegener       Date:  2021-07-02       Impact factor: 14.195

Review 10.  Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches.

Authors:  Rashad Hussain; Hira Zubair; Sarah Pursell; Muhammad Shahab
Journal:  Brain Sci       Date:  2018-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.